News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter

Published Papers Endorse NanoSight Limited Technology

7/16/2013 9:03:25 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

Salisbury, UK, 16th July, 2013: NanoSight, world-leading providers of unique nanoparticle characterization technology, announces that more than 800 third party publications citing their Nanoparticle Tracking Analysis (NTA) methodology have been published, and reflect on the significance of this powerful third party endorsement.

May 2013 saw publication of the 800th peer-reviewed paper citing NTA. It was written by Mark Davis and his group at Caltech: "Transcytosis and brain uptake of transferrin-containing nanoparticles by tuning avidity to transferrin receptor." It was published in the Proceedings of the National Academy of Sciences of the United States of America. This is an open access publication and is freely available at

Since the first papers referencing NTA appeared in 2006, the rate of publication has grown exponentially.

The proportion of papers within Life Sciences has grown most rapidly, from 30% in the early years to more than 80% today. This bias is driven by the match between NanoSight's multiparameter characterization capability and the complexity and natural variability of biological and botanical samples. "Publications are largely from academic users; commercial concerns remain more guarded about applications, for good business reasons. With these users, primarily in the pharmaceutical industries, we do have to work harder to understand their applications and future needs," commented Jeremy Warren, NanoSight's CEO.

Since NanoSight began sales in earnest in 2006, uptake has been rapid; today the instrument population exceeds 600 with more than 90% of sales outside the UK. Providing instruments is just the start of the adoption process. Only when users validate the usefulness of new measurands can the potential of any new technology be fully appreciated.

"User endorsement carries far more weight than anything we could say about NTA" says NanoSight's Head of Development, Dr Patrick Hole. "Users tell colleagues in the same field about NanoSight's utility, and that is emphasized best when a paper is published. Peers see this information together with the value that the characterization provides along with a record of the methodologies employed."

Applications range from drug delivery system and aggregation of protein therapeutics to legislation-driven nanomaterials detection and study of exosomes. Exosomes are biologically derived nanoparticles whose enormous potential in cancer and other diagnostics is driving a burgeoning sector of scientific research.

For Warren, papers provide horsepower to the innovation and development processes. He comments "Fundamental to our business is the development of new applications. Within the miscellany of unique applications of NanoSight instrumentation sit occasional nuggets of gold. These are the applications that tick all the boxes: the data NanoSight supplies is unique, it is extremely valuable to the user and the sector is large and growing. Users bring these to us; our task is to listen."

New applications aside, papers represent development effort. Warren adds "reflect for a moment on hundreds of research groups' writing papers. In 2013 this will represent tens of thousands of laboratory hours from PhD-level scientists, with their NanoSight work continuing to advance research and development." Warren concludes "The publication rate continues upward and, if current trends continue, 2013 will see papers reach the 1,000 mark. Now that will be a milestone to celebrate."

A complete list of papers is available at and a book reviewing all papers published from 2010 to 2012 is also available at

About NanoSight:

NanoSight delivers the world's most versatile and proven multi-parameter nanoparticle analysis in a single instrument. NanoSight's "Nanoparticle Tracking Analysis" (NTA) detects and visualizes populations of nanoparticles in liquids down to 10 nm, dependent on material, and measures the size of each particle from direct observations of diffusion. Additionally, NanoSight measures concentration while a fluorescence mode differentiates suitably-labelled particles within complex background suspensions. Zeta potential measurements are similarly particle-specific. It is this particle-by-particle methodology that takes NTA beyond traditional light scattering and other ensemble techniques in providing high-resolution particle size distributions and validates data with information-rich video files of the particles moving under Brownian motion.

This simultaneous multiparameter characterization matches the demands of complex biological systems, hence its wide application in development of drug delivery systems, of viral vaccines, and in nanotoxicology. This real-time data gives insight into the kinetics of protein aggregation and other time-dependent phenomena in a qualitative and quantitative manner. NanoSight has a growing role in biodiagnostics, being proven in detection and speciation of nanovesicles (exosomes) and microvesicles.

NanoSight has installed more than 600 systems worldwide with users including BASF, GlaxoSmithKline, Merck, Novartis, Pfizer, Proctor and Gamble, Roche and Unilever together with the most eminent universities and research institutes. NanoSight's technology is validated by 850+ third party papers citing NanoSight results. NanoSight's leadership position in nanoparticle characterization is consolidated further with publication of an ASTM International standard, ASTM E2834, which describes the NTA methodology for detection and analysis of nanoparticles. For more information, visit

For further information:

Please contact NanoSight direct or their marketing agency, Talking Science:

NanoSight Limited

Minton Park

London Road

Amesbury SP4 7RT UK

T +44(0)1980 676060

F +44(0)1980 624703

Talking Science Limited

39 de Bohun Court

Saffron Walden

Essex CB10 2BA UK

T +44(0)1799 521881

M +44(0)7843 012997

Help employers find you! Check out all the jobs and post your resume.

Read at

comments powered by Disqus